BLRXBioLineRx Ltd.

Nasdaq biolinerx.com


$ 0.62 $ 0.04 (6.31 %)    

Friday, 26-Apr-2024 15:57:07 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 0.6116
$ 0.55
$ 0.60 x 600
$ 0.00 x 0
$ 0.55 - $ 0.62
$ 0.55 - $ 2.53
582,908
na
44.3M
$ 1.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 biolinerx-announces-6m-registered-direct-offering-of-75m-ads-and-warrants-to-purchase-up-to-an-aggregate-of-75m-adss-at-a-combined-purchase-price-of-080-per-ads-and-accompanying-warrant

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical ...

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 bioline-rx-q4-eps-015-beats-022-estimate-sales-480m

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by...

 earnings-scheduled-for-march-26-2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

 earnings-preview-for-bioline-rx
Earnings Preview For BioLine Rx
03/25/2024 15:02:32

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 earnings-scheduled-for-november-20-2023

Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 ...

 bioline-rx-q3-eps-001-may-not-be-comparable-to-021-estimate

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.21) by...

 bioline-rx-earnings-preview
BioLine Rx Earnings Preview
11/17/2023 14:01:47

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION